13,977 reports of this reaction
4.9% of all CYCLOPHOSPHAMIDE INJECTION, SOLUTION reports
#2 most reported adverse reaction
FEBRILE NEUTROPENIA is the #2 most commonly reported adverse reaction for CYCLOPHOSPHAMIDE INJECTION, SOLUTION, manufactured by Alembic Pharmaceuticals Inc.. There are 13,977 FDA adverse event reports linking CYCLOPHOSPHAMIDE INJECTION, SOLUTION to FEBRILE NEUTROPENIA. This represents approximately 4.9% of all 284,200 adverse event reports for this drug.
Patients taking CYCLOPHOSPHAMIDE INJECTION, SOLUTION who experience febrile neutropenia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FEBRILE NEUTROPENIA is moderately reported among CYCLOPHOSPHAMIDE INJECTION, SOLUTION users, representing a notable but not dominant share of adverse events.
In addition to febrile neutropenia, the following adverse reactions have been reported for CYCLOPHOSPHAMIDE INJECTION, SOLUTION:
The following drugs have also been linked to febrile neutropenia in FDA adverse event reports:
FEBRILE NEUTROPENIA has been reported as an adverse event in 13,977 FDA reports for CYCLOPHOSPHAMIDE INJECTION, SOLUTION. This does not prove causation, but indicates an association observed in post-market surveillance data.
FEBRILE NEUTROPENIA accounts for approximately 4.9% of all adverse event reports for CYCLOPHOSPHAMIDE INJECTION, SOLUTION, making it one of the most commonly reported side effect.
If you experience febrile neutropenia while taking CYCLOPHOSPHAMIDE INJECTION, SOLUTION, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.